Lakefront Biotherapeutics (LKFT) Current Deferred Revenue (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Current Deferred Revenue for 13 consecutive years, with $36414.5 the latest figure, recorded in Q1 2026.

• Quarterly Current Deferred Revenue fell 99.99% year-over-year to $36414.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36414.5 (down 99.99% YoY) and the FY2025 annual result came in at $36414.5, down 99.99% from the prior year.
• Current Deferred Revenue steadied at $36414.5 in Q1 2026 per LKFT's latest filing, from $36414.5 in the prior quarter.
• Over the last five years, Current Deferred Revenue for LKFT reached as high as $475.8 million in Q1 2022 and fell as low as $36414.5 in Q4 2025.
• A 5-year average of $270.8 million and a median of $264.5 million in 2024 frame the typical range for Current Deferred Revenue.
• The largest YoY upside for Current Deferred Revenue was 0.35% in 2025 against a maximum downside of 99.99% in 2025.
• Year by year, Current Deferred Revenue stood at $416.1 million in 2022, then declined by 29.91% to $291.6 million in 2023, then decreased by 9.28% to $264.5 million in 2024, then tumbled by 99.99% to $36414.5 in 2025, then changed by 0.0% to $36414.5 in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $36414.5, $36414.5, and $261.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.